Neurocrine Biosciences, Inc. [NBIX] stock prices are up 0.77% to $117.34 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NBIX shares have gain 5.09% over the last week, with a monthly amount drifted -4.02%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on August 29, 2024, and elevated its price target to $159. On April 24, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Deutsche Bank initiated its recommendation with a Buy and recommended $136 as its price target on December 12, 2023. In a note dated August 21, 2023, Mizuho reiterated an Neutral rating on this stock and boosted its target price from $112 to $113.
The stock price of Neurocrine Biosciences, Inc. [NBIX] has been fluctuating between $103.63 and $157.98 over the past year. Currently, Wall Street analysts expect the stock to reach $148.1 within the next 12 months. Neurocrine Biosciences, Inc. [NASDAQ: NBIX] shares were valued at $117.34 at the most recent close of the market. An investor can expect a potential return of 26.21% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
The Neurocrine Biosciences, Inc. [NASDAQ:NBIX] reported sales of 2.12B for trailing twelve months, representing a surge of 30.37%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.16%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.15 and Total Capital is 0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 116.38 points at the first support level, and at 115.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 118.13, and for the 2nd resistance point, it is at 118.93.
Ratios To Look Out For
It’s worth pointing out that Neurocrine Biosciences, Inc. [NASDAQ:NBIX]’s Current Ratio is 4.19. In addition, the Quick Ratio stands at 4.08 and the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 5.59, the price to book ratio is 4.72 and price to earnings (TTM) ratio is 35.45.
Transactions by insiders
Recent insider trading involved Boyer David W., Chief Corp. Affairs Officer, that happened on Sep 13 ’24 when 3461.0 shares were sold. Officer, DAVID WARREN BOYER completed a deal on Sep 13 ’24 to buy 4756.0 shares. Meanwhile, Director RASTETTER WILLIAM H sold 14250.0 shares on Aug 15 ’24.
